Combination therapy for multiple myeloma
Authors:
Abstract
The effect of six different chemotherapy regimens were evaluated in 462 previously untreated patients with multiple myeloma. In comparison with other treatments, drug combinations that included vincristine and were given at 3-week intervals were associated with higher response rates and longer survival times. No gain was noted from the use of Adriamycin or from combinations of alkylating agents unless vincristine was given and the treatment intervals were short. Seventy-one responding patients were allocated at random to maintenance treatment with intermittent courses of either azathioprine-prednisone or a combination of melphalan-cyclophosphamide-carmustine (BCNU)-prednisone. The survival time was not prolonged with either maintenance treatment in comparison with that for responding patients continued on other therapies or on no therapy in previous studies. Attempts to reduce tumor mass maximally with a change in the therapeutic modality, such as with immunotherapy or radiotherapy, remain to be evaluated. Cancer 40:2765-2771, 1977.Keywords
This publication has 11 references indexed in Scilit:
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976
- Prognostic factors in multiple myelomaCancer, 1975
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- Treatment of MyelomaArchives of internal medicine (1960), 1975
- Monoclonal Gammopathy in LymphomaArchives of internal medicine (1960), 1975
- Expansion of the growth fraction in multiple myeloma with alkylating agentsBlood, 1975
- Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNUCancer, 1974
- Combination chemotherapy for multiple myelomaCancer, 1972
- Treatment for Multiple MyelomaJAMA, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958